# SHC4

## Overview
SHC4, also known as ShcD, is a gene that encodes the SHC adaptor protein 4, a member of the Shc family of adaptor proteins involved in signal transduction. This protein is characterized by its phosphotyrosine binding (PTB) and Src homology 2 (SH2) domains, which facilitate interactions with phosphorylated tyrosine residues on receptor tyrosine kinases (RTKs) and other signaling proteins (Jones2007Analysis). SHC4 is primarily expressed in the brain and skeletal muscle, where it plays a critical role in modulating signaling pathways, particularly those associated with the neuromuscular junction and neurotrophic factor receptors (Wills2017Signaling; Jones2007Analysis). The protein's unique structural features, including a distinct collagen homology 1 (CH1) region and specific tyrosine phosphorylation sites, contribute to its specialized functions in cellular signaling and its involvement in pathological conditions such as cancer (Zhang2022SHC4; Jones2007Analysis).

## Structure
SHC4, also known as ShcD, is a member of the Shc family of adaptor proteins, characterized by specific domains that facilitate its role in signal transduction. The protein structure includes an amino-terminal phosphotyrosine binding (PTB) domain and a carboxy-terminal Src homology 2 (SH2) domain, which are crucial for binding to phosphorylated tyrosine residues on receptor tyrosine kinases (RTKs) and other signaling proteins (Jones2007Analysis). The central region of SHC4 contains a collagen homology 1 (CH1) region with phosphorylatable tyrosine residues, including a unique tyrosine at position 424 that serves as a binding site for the SH2 domain of Grb2, enhancing its signaling capabilities (Jones2007Analysis).

SHC4 is expressed as multiple isoforms, with the primary isoform being approximately 75 kDa in size (Jones2007Analysis). The CH1 region of SHC4 lacks the adaptin-binding motif found in other Shc proteins, and the CH2 region is extended, containing unique proline-rich motifs that may serve as recognition sites for SH3 domain-containing proteins (Jones2007Analysis). These structural features contribute to SHC4's distinct signaling roles, particularly in the brain and skeletal muscle (Jones2007Analysis).

## Function
SHC4, also known as ShcD, is a member of the Shc family of adaptor proteins involved in signal transduction pathways. In healthy human cells, SHC4 plays a critical role in various signaling processes, particularly those mediated by receptor tyrosine kinases (RTKs). It is primarily expressed in the brain and skeletal muscle, where it associates with the muscle-specific kinase (MuSK) receptor. SHC4 binds to phosphorylated MuSK via its phosphotyrosine binding (PTB) domain and undergoes tyrosine phosphorylation downstream of activated MuSK. This interaction is significant at the neuromuscular junction, where it contributes to the early tyrosine phosphorylation of acetylcholine receptors, essential for synaptic transmission (Jones2007Analysis).

SHC4 also interacts with neurotrophic factor receptors such as Ret, TrkA, and TrkB in the nervous system. It binds these receptors through its PTB domain and suppresses the phosphorylation of Erk MAPK, a key signaling molecule, by affecting the recruitment of signaling components like Grb2 and Shp2. This suppression suggests a unique role for SHC4 in modulating signaling pathways in neural cells, potentially impacting cell survival and differentiation (Wills2017Signaling). The presence of unique tyrosine phosphorylation sites, including a novel Grb2 binding site, further indicates its distinct role in cellular signaling processes (Jones2007Analysis).

## Clinical Significance
Alterations in the expression of the SHC4 gene have been implicated in various cancers. In prostate cancer, SHC4 is targeted by miR-26a, which regulates extracellular vesicle (EV) secretion. The suppression of SHC4, along with PFDN4 and CHORDC1, by miR-26a leads to reduced EV secretion and decreased tumorigenesis, suggesting that SHC4 plays a role in cancer progression through its involvement in EV biogenesis (Urabe2020miR26a).

In hepatocellular carcinoma (HCC), SHC4 is significantly upregulated and associated with aggressive tumor characteristics and poor prognosis. SHC4 overexpression enhances tumor proliferation, metastasis, and epithelial-mesenchymal transition (EMT) by activating STAT3 signaling. Knockdown of SHC4 reduces these oncogenic processes, indicating its role as a carcinogenic factor in HCC (Zhang2022SHC4).

SHC4 is also overexpressed in other cancers, such as melanomas and gliomas, where it contributes to tumor growth and invasion. Its role in these cancers may involve interactions with signaling pathways like MAPK/Erk, where it can modulate phosphorylation events and influence cellular outcomes (Wills2017Signaling). These findings highlight SHC4 as a potential therapeutic target in various malignancies.

## Interactions
SHC4, also known as ShcD, is a member of the Shc family of adaptor proteins and is involved in various protein interactions, particularly with receptor tyrosine kinases. One of its primary interactions is with the muscle-specific kinase (MuSK) receptor. SHC4 associates with MuSK through its phosphotyrosine binding (PTB) domain, which binds to the phosphorylated juxtamembrane NPXY motif of MuSK. This interaction is crucial for the tyrosine phosphorylation of SHC4 and subsequent signaling events (Jones2007Analysis).

SHC4 also interacts with the Grb2 protein through unique tyrosine phosphorylation sites, such as Y424, which are not found in other Shc proteins. These sites facilitate the recruitment of Grb2, enhancing SHC4's signaling capabilities, particularly in early Ras activation (Jones2007Analysis).

In the context of cancer, SHC4 is implicated in the activation of the STAT3 signaling pathway in hepatocellular carcinoma (HCC). Overexpression of SHC4 in HCC cells leads to increased phosphorylation of STAT3, promoting tumor proliferation and metastasis (Zhang2022SHC4). These interactions highlight SHC4's role in both normal cellular signaling and pathological conditions.


## References


[1. (Wills2017Signaling) Melanie K.B. Wills, Ava Keyvani Chahi, Hayley R. Lau, Manali Tilak, Brianna D. Guild, Laura A. New, Peihua Lu, Kévin Jacquet, Susan O. Meakin, Nicolas Bisson, and Nina Jones. Signaling adaptor shcd suppresses extracellular signal-regulated kinase (erk) phosphorylation distal to the ret and trk neurotrophic receptors. Journal of Biological Chemistry, 292(14):5748–5759, April 2017. URL: http://dx.doi.org/10.1074/jbc.m116.770511, doi:10.1074/jbc.m116.770511. This article has 8 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m116.770511)

[2. (Zhang2022SHC4) Xin Zhang, Hongwei Zhang, Zhibin Liao, Jiacheng Zhang, Huifang Liang, Weixing Wang, Jia Yu, and Keshuai Dong. Shc4 promotes tumor proliferation and metastasis by activating stat3 signaling in hepatocellular carcinoma. Cancer Cell International, January 2022. URL: http://dx.doi.org/10.1186/s12935-022-02446-9, doi:10.1186/s12935-022-02446-9. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-022-02446-9)

[3. (Jones2007Analysis) Nina Jones, W. Rod Hardy, Matthew B. Friese, Claus Jorgensen, Matthew J. Smith, Neil M. Woody, Steven J. Burden, and Tony Pawson. Analysis of a shc family adaptor protein, shcd/shc4, that associates with muscle-specific kinase. Molecular and Cellular Biology, 27(13):4759–4773, July 2007. URL: http://dx.doi.org/10.1128/MCB.00184-07, doi:10.1128/mcb.00184-07. This article has 82 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.00184-07)

[4. (Urabe2020miR26a) Fumihiko Urabe, Nobuyoshi Kosaka, Yurika Sawa, Yusuke Yamamoto, Kagenori Ito, Tomofumi Yamamoto, Takahiro Kimura, Shin Egawa, and Takahiro Ochiya. Mir-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting shc4, pfdn4, and chordc1. Science Advances, May 2020. URL: http://dx.doi.org/10.1126/sciadv.aay3051, doi:10.1126/sciadv.aay3051. This article has 44 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/sciadv.aay3051)